Literature DB >> 2119169

Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors.

P F Kador1, Y Akagi, Y Takahashi, H Ikebe, M Wyman, J H Kinoshita.   

Abstract

Vascular changes associated with early diabetic retinopathy that include the selective degeneration of pericytes, the formation of microaneurysms and acellular capillaries, and vessel dilation have been experimentally investigated in age- and sex-matched beagle dogs fed a 30% galactose diet and treated with or without the aldose reductase inhibitors sorbinil and/or M79175. Eyes from dogs in each group were periodically enucleated during a 36-month period and their retinal capillaries were examined as trypsin-digested flat preparations. These studies reveal that the destruction of retinal pericytes to form pericyte ghosts is the earliest observable retinal vessel change occurring after 19 to 21 months of galactose feeding. By 24 months, both an irregular distribution of endothelial cell nuclei near pericyte ghosts and the presence of acellular capillaries containing neither endothelial cells nor pericytes can be observed. This was followed by the histologic appearance of microaneurysms after 27 months and the funduscopic appearance of intraretinal hemorrhages after 33 months. Varicose enlargements of capillaries were also observed in the trypsin-digested preparations from dogs fed galactose for 33 to 36 months. All of these changes are linked to the initial aldose reductase-associated destruction of pericytes. The onset and progression of these retinal changes were retarded in a dose-dependent manner with aldose reductase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2119169     DOI: 10.1001/archopht.1990.01070110117035

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  24 in total

Review 1.  Pathophysiology of Diabetic Retinopathy: Contribution and Limitations of Laboratory Research.

Authors:  Timothy S Kern; David A Antonetti; Lois E H Smith
Journal:  Ophthalmic Res       Date:  2019-07-30       Impact factor: 2.892

Review 2.  Diabetic retinopathy.

Authors:  E M Kohner
Journal:  BMJ       Date:  1993-11-06

3.  Experimental nonenzymatic glycosylation of vitreous collagens occurs by two pathways.

Authors:  J S Pulido
Journal:  Trans Am Ophthalmol Soc       Date:  1996

4.  Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug.

Authors:  T A Gardiner; H R Anderson; T Degenhardt; S R Thorpe; J W Baynes; D B Archer; A W Stitt
Journal:  Diabetologia       Date:  2003-07-12       Impact factor: 10.122

5.  Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.

Authors:  M L McCaleb; M L McKean; T C Hohman; N Laver; W G Robison
Journal:  Diabetologia       Date:  1991-10       Impact factor: 10.122

6.  Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium.

Authors:  S A Vinores; E Van Niel; J L Swerdloff; P A Campochiaro
Journal:  Histochem J       Date:  1993-09

7.  Correlation between erythrocyte aldose reductase level and human diabetic retinopathy.

Authors:  N Oishi; E Kubo; Y Takamura; K Maekawa; T Tanimoto; Y Akagi
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

Review 8.  Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.

Authors:  Sally A Madsen-Bouterse; Renu A Kowluru
Journal:  Rev Endocr Metab Disord       Date:  2008-12       Impact factor: 6.514

Review 9.  The role of polyols in the pathophysiology of hypergalactosemia.

Authors:  G T Berry
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

Review 10.  Galactosemia unsolved.

Authors:  S Segal
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.